Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers February 15, 2019
Pharmacy Choice - News - Over-the-Counter Drugs - February 15, 2019

Pharmacy News

 Over-the-Counter Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 23 of 23     Go To Page:

2/14/19 - A state law that went into effect last month should make it easier for people to safely dispose of surplus prescription and
A state law that went into effect last month should make it easier for people to safely dispose of surplus prescription and non-prescription drugs. "For people addicted to opioids, the first supply often comes from a friend or family member who has a significant supply of medication left over," said Stephen A. Jennings, chairman of the Alliance fo
2/14/19 - Branded Generics Market Foreseen to Grow at 7.3% CAGR by 2026: Increasing prevalence of chronic and lifestyle diseases expected to create demand for branded generics over the assessment period
Valley Cottage, NY 02/14/2019 Differential and innovative product strategies that are adopted by various multinational pharma companies have been fuelling the growth of branded generics market at a global scale. These strategies include establishing sustained local capabilities with the strong local talents, engaging in portfolio marketing,..
2/14/19 - HEALTH & SUPPORT
Monday evenings at 63 Jefferson Ave., Salem; and from noon to 1:30 p.m. Fridays at 75 Lindall St., Danvers. The Beverly and Addison Gilbert Hospital's Speakers Bureau is a free service designed to bring timely information on a variety of health-related topics. Held 7-8: 30 p.m. on the last Wednesday of each month in the doctors' conference room at
2/14/19 - Perrigo Announces Patent Litigation Settlement for the Generic Version of Jublia Topical Solution 10%
DUBLIN- Perrigo Company plc, a leading global provider of' Quality, Affordable Self-care Products', today announced that it has settled its Hatch-Waxman litigation relating to its first-to-file Abbreviated New Drug Application for the generic equivalent to Jublia Topical Solution 10% brought by Valeant Pharmaceuticals North America LLC, Valeant...
2/13/19 - $34.5 Bn Dermatology Drugs Market 2018 - Global Forecast to 2023 - Humira, Remicade, Otezla, Stelara, Enbrel, Cosentyx, Neoral, Taltz, Cubicin, Canesten, Zyvox, Dupixent, Protopic, Valtrex, & Eucrisa
Dermatology drugs market is expected to reach $34.5 billion by 2023, increasing personal spending, strong pipeline of dermatological drugs, and growing awareness about skin diseases are the key factors boosting the demand for dermatology drugs globally. On the basis of treatment, the dermatology drugs market has been categorized into topical...
2/13/19 - Alvogen and Lotus Launch the First Generic Equivalent to Revlimid? Capsules in Selected European Countries
Global pharmaceutical company, Alvogen, today announced the launch of the first generic equivalent of Revlimid? in a range of its operating CEE markets including Romania, Croatia, Bulgaria and the Baltic states. By the time of Alvogen launch, Revlimid? is perceived as the single biggest-selling oncology drug with approximately $9.8 billion sale
2/13/19 - Healthy Directions and Adaptive Health Announce the Introduction of a Clinically-Studied Pain Relief Cream in the Popular Instaflex Product Line
Healthy Directions LLC, and its parent company, Adaptive Health, LLC, have teamed up to add a clinically-studied pain relief cream to the bestselling Instaflex line of nutritional supplements. While athletes in Europe have been using oxygenated oil for years, it took Dr. Joseph Pergolizzi, a leading expert in pain medicine, to bring it to the
2/13/19 - Perrigo Announces Patent Litigation Settlement for the Generic Version of Jublia Topical Solution 10%
Perrigo Company plc, a leading global provider of "Quality, Affordable Self-care Products?", today announced that it has settled its Hatch-Waxman litigation relating to its first-to-file Abbreviated New Drug Application for the generic equivalent to Jublia Topical Solution 10% brought by Valeant Pharmaceuticals North America LLC, Valeant...
2/13/19 - Pharma-Grade Synthetic Camphor Market: Consumption Soars as Private Labeled Products Increase
Albany, NY 02/13/2019 Preferably obtained from turpentine oil, pharma-grade synthetic camphor has had a surge in applications in fine chemistry procedures, medical formulations and hygiene products. Augmenting sales in retail sector coupled with lower rates of side effects vis-a-vis oral analgesics are projected to up the demand in medical in
2/13/19 - What goes into some of the world's innovative, life-changing cancer medications [Bizcommunity (South Africa)]
Next time you or a loved-one take medication, whether an over-the-counter pain-killer, chronic medication, or a breakthrough treatment, take a moment to think about its origins... In 2017 alone, Roche invested R139.7bn in research and development, and currently has 22,747 employees dedicated to designing, testing and refining life enhancing medicat
2/12/19 - "Managing Pain During the Opioid Crisis."
Andrew Coop and I am a Professor of Pharmaceutical Sciences in the University of Maryland's School of Pharmacy. As many of you know, the school is located at the University of Maryland, Baltimore in the City of Baltimore- a densely urban area of this country which has its share of the many challenges US cities face. In the interest of transparency,
2/12/19 - Alvogen and Lotus launch the first generic equivalent to Revlimid? capsules in selected European countries
Alvogen, today announced the launch of the first generic equivalent of Revlimid (TM) in a range of its operating CEE markets including Romania, Croatia, Bulgaria and the Baltic states. Following the launch into CEE, the generic and bioequivivalent version of Revlimid (TM) will be launched globally in 2019, having been developed in-house at Alvogen'
2/12/19 - BioElectronics Files FDA Applications for Treatment of Musculoskeletal & Postoperative Pain
via NEWMEDIAWIRE BioElectronics Corporation, www.bielcorp.com is pleased to announce that two Traditional 510 Premarket Notification applications were filed with the U.S. Food and Drug Administration. The applications were for the ActiPatch and RecoveryRx medical devices for market clearances of over-the-counter adjunctive treatment of
2/12/19 - Moberg Pharma Divests Its OTC-business for USD 155 Million and Secures New Funding for MOB-015 in Transformational Transaction
Moberg Pharma AB today announces that it has entered into agreement with a holding company owned by RoundTable Healthcare Partners and Signet Healthcare Partners to divest MPJ OTC AB and Moberg Pharma North America LLC, which at closing will hold Moberg Pharma's entire OTC-business, for a cash consideration of USD 155 million adjusted for working
2/12/19 - Regeneron and Sanofi Offer Praluent at a New Reduced U.S. List Price
TARRYTOWN- Regeneron Pharmaceuticals, Inc. and Sanofi today announced that Praluent will be made available at a new reduced U.S. list price of $5, 850 annually, a 60% reduction from the original price, for both the 75 mg and 150 mg doses, beginning in early March. This follows an earlier announcement in March 2018, when Regeneron and Sanoficommitte
2/12/19 - Various Medicinal Products [TendersInfo (India)]
Contract notice: Various medicinal products. various prescription and non-prescription drugs, Bandages, Medical aids and other preparations in the amount of 300,000,000 huf/ 24 month net for pharmacies offering prescription and prescription medicines to retail pharmacies operating in the contracting authority. Wholesale prices of medicines that can
2/11/19 - ELITE PHARMACEUTICALS INC /NV/ - 10-Q - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
COMPARED TO THE THREE AND NINE MONTHS ENDED DECEMBER 31, 2017 The following discussion of our financial condition and results of operations for the three and nine months ended December 31, 2018 and 2017 should be read in conjunction with our unaudited condensed consolidated financial statements and the notes to those statements that are included...
2/11/19 - EMA - New safety features for medicines sold in the EU
As of 9 February 2019, most prescription medicines and some over-the-counter medicines for human use supplied in the European Union are required to have a unique identifier and an anti-tampering device on their outer packaging. The safety features are implemented through a delegated regulation that comes into application on 9 February 2019.
2/11/19 - Global Pharma and Healthcare Social Media Marketing Set for Rapid Growth and Trend: Future Market Insights has announced the addition of the Pharma and Healthcare Social Media Marketing: Global Industry Analysis and Opportunity Assessment 2015 - 2
Valley Cottage, NY 02/11/2019 Social media platforms refer to the interaction among the people that involves creation, sharing and exchange of information and ideas in virtual networks and communities. For instance, in second week of January 2014, the U.S. Food and Drug Administration released a guidance draft for industry that needs to fulfi
2/11/19 - Regeneron and Sanofi Offer Praluent (alirocumab) at a New Reduced U.S. List Price
Beginning in early March 2019, new U.S. National Drug Code options will be available at approximately 60% less than the original price. Regeneron Pharmaceuticals, Inc. and Sanofi today announced that Praluent will be made available at a new reduced U.S. list price of $5,850 annually, a 60% reduction from the original price, for both the 75 mg an
2/11/19 - Sanofi and Regeneron offer Praluent (alirocumab) at a new reduced U.S. list price
BRIDGEWATER, N.J. and TARRYTOWN, N.Y., Feb. 11, 2019/ PRNewswire/ Praluent will be made available at a new reduced U.S. list price of $5,850 annually, a 60% reduction from the original price, for both the 75 mg and 150 mg doses, beginning in early March. This follows an earlier announcement in March 2018, when Sanofi and Regeneron committed to
2/9/19 - New safety features for medicines sold in the EU
LONDON, 08 February 2019/ PRNewswire Policy/ As of 9 February 2019, most prescription medicines and some over-the-counter medicines for human use supplied in the European Union are required to have a unique identifier and an anti-tampering device on their outer packaging. The safety features are implemented through a delegated regulation that com
2/8/19 - New safety features for medicines sold in the EU - Questions & Answers
BRUSSELS, 08 February 2019/ PRNewswire Policy/ What are falsified medicines and why are they a problem in the EU? Falsified Medicines are fake medicines that pass as real, authorised medicines. Falsified medicines may contain ingredients, including active ingredients, which are of low quality or in the wrong dosage either too high or too low.
Articles(s): 1 - 23 of 23     Go To Page:


© 2019 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2019 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415